BCX-1898
BCX-1898, a cyclopentane derivative, is an orally active and selective influenza virus neuraminidase inhibitor. BCX-1898 has antiviral activity with EC50s of <0.01-21 μM on influenza A (H1N1, H3N2, and H5N1) and influenza B viruses replication in MDCK cells. BCX-1898 shows protection against the mouse influenza model.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 345267-14-3
- Fòrmula: C17H32N4O3
- Peso molecular:340.46
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Descripciòn
In Vivo
BCX-1898 (0.01, 0.1 mg/kg/day; intranasal treatment; 20 days) demonstrates complete protection (10 out of 10 survived)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice (13-18 g) infected with the A/Turkey/Mas/ 76 X A/Beijing/32/92 (H6N2) influenza virus[2]
-
Dosage:1, 10 mg/kg/day
-
Administration:Oral; 22 days
-
Result:Showed complete protection against the influenza virus with 10 mg/kg/day, whereas at dose level (1 mg/kg/day) showed only a 10% protection against the influenza virus.
Chemical Information
-
No. CAS 345267-14-3
-
Peso molecular 340.46
-
Fòrmula C17H32N4O3
-
SMILES
CCCC(CCC)[C@@H]([C@]1([H])[C@@H](C[C@@H](C1)C(O)=O)NC(N)=N)NC(C)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocolo
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Pureza y Documentación
Referencias
[1]. D F Smee, et al. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob Agents Chemother. 2001 Mar;45(3):743-8. [Content Brief]
[2]. Pooran Chand, et al. Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamivir and zanamivir in vivo. Bioorg Med Chem. 2005 Jun 2;13(12):4071-7. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
BCX-1898 Related Classifications
HY-105395 Related Classifications
Powered by Bioz